Acesion Pharma commences phase one study in atrial fibrillation

Rachel Cresswell 12 March 2018

Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, has announced that it has commenced the clinical study for its lead compound AP30663.

AP30663 has successfully completed the preclinical development program demonstrating a good safety profile and efficacy in converting AF to a normal sinus rhythm. The phase 1 study is a randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in 48 healthy subjects. The trial is expected to be completed in June 2018 with data expected by the end of August 2018. The trial is being conducted at the Centre for Human Drug Research (CHDR) in the Netherlands.

Atrial fibrillation is the most common cardiac arrhythmia, affecting at least 10 million people in the US and Europe and 30 million people worldwide. The incidence of AF increases with age and it is estimated that 5-10% of the population above the age of 70 have AF. It is a progressive disease with incapacitating symptoms, which decrease the health-related quality of life and is associated with significant morbidity including a 5-fold increased risk of stroke and a two-fold increase in mortality.

Acesion’s novel approach is based on inhibition of SK channels - ion channels present in the atria that play a role in regulating the cardiac rhythm. Blocking these ion channels with a functionally atrial selective drug helps avoid deleterious effects on the ventricles. Targeting the SK channels thereby constitutes a novel and promising approach for an effective treatment of AF with an expected higher safety and tolerability profile.


Make a comment

To voice your opinion, please Log in or Register.

Pf Magazine

Your resource for news, features, interviews, careers and events in the pharma industry.

Click here for the latest issue and to subscribe.